Profile data is unavailable for this security.
About the company
Sareum Holdings plc is a United-Kingdom based holding company. It is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry, and medicinal chemistry. Its drug programs include Checkpoint Kinase 1 (Chk1), TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer and Aurora+FLT3 Kinase. The Checkpoint Kinase 1 (Chk1) inhibitor SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and central mediator of the DNA damage response (DDR) network. The TYK2/JAK1 are both members of the Janus kinase (JAK) family of protein kinase enzymes with important roles in maintaining a healthy immune system. Both kinases promote inflammatory responses in autoimmune diseases, respiratory infections and tumor cell proliferation in certain cancers. Aurora+FLT3 Kinase Programme targets Acute Myeloid Leukemia (AML) and other blood cancers.
- Revenue in GBP (TTM)0.00
- Net income in GBP-1.81m
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 122 349 7700
- Fax+44 122 349 7701